Privium Fund Management B.V. Buys 3,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Privium Fund Management B.V. raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 11.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 30,347 shares of the company’s stock after purchasing an additional 3,000 shares during the quarter. Privium Fund Management B.V.’s holdings in CRISPR Therapeutics were worth $1,426,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in CRSP. SFE Investment Counsel raised its holdings in CRISPR Therapeutics by 3.6% in the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after acquiring an additional 203 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after purchasing an additional 211 shares in the last quarter. Orion Capital Management LLC lifted its position in CRISPR Therapeutics by 44.0% in the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after purchasing an additional 220 shares during the period. National Bank of Canada FI boosted its stake in CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after buying an additional 220 shares in the last quarter. Finally, Larson Financial Group LLC increased its holdings in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after buying an additional 276 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $51.62 on Friday. The company’s 50 day simple moving average is $47.45 and its 200 day simple moving average is $52.18. CRISPR Therapeutics AG has a fifty-two week low of $43.42 and a fifty-two week high of $91.10. The firm has a market capitalization of $4.41 billion, a P/E ratio of -18.24 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period last year, the company earned ($1.41) EPS. Sell-side analysts expect that CRISPR Therapeutics AG will post -5.47 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on CRSP shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Stifel Nicolaus decreased their price objective on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Truist Financial dropped their target price on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $74.94.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.